BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33822285)

  • 1. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis.
    Girón-Ortega JA; Márquez-Coello M; Gutiérrez-Saborido D; Arizcorreta A; Cuesta-Sancho S; Girón-González JA
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1863-1871. PubMed ID: 33822285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
    BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
    J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    López-Cortés LF; Trujillo-Rodríguez M; Báez-Palomo A; Benmarzouk-Hidalgo OJ; Dominguez-Molina B; Milanés-Guisado Y; Espinosa N; Viciana P; Gutiérrez-Valencia A
    J Infect Dis; 2018 Jul; 218(4):624-632. PubMed ID: 29986086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
    Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
    PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
    Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
    Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
    Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
    AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4
    Polo ML; Ghiglione YA; Salido JP; Urioste A; Poblete G; Sisto AE; Martinez A; Rolón MJ; Ojeda DS; Cahn PE; Turk GJ; Laufer NL
    J Int AIDS Soc; 2019 Sep; 22(9):e25375. PubMed ID: 31536177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of hepatic FOXP3+ T-lymphocytes in HIV/hepatitis C coinfection.
    Williams SK; Donaldson E; Van der Kleij T; Dixon L; Fisher M; Tibble J; Gilleece Y; Klenerman P; Banham AH; Howard M; Webster DP
    J Viral Hepat; 2014 Apr; 21(4):251-9. PubMed ID: 24597693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.
    Auma AWN; Shive CL; Kostadinova L; Anthony DD
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment.
    Ryscavage P; Hussien S; Seung H; Hynicka L
    HIV Med; 2024 May; 25(5):622-627. PubMed ID: 38273652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of DAA-mediated HCV eradication on CD4
    Bandera A; Lorenzini P; Taramasso L; Cozzi-Lepri A; Lapadula G; Mussini C; Saracino A; Ceccherini-Silberstein F; Puoti M; Quiros-Roldan E; Montagnani F; Antinori A; d'Arminio Monforte A; Gori A;
    J Viral Hepat; 2021 May; 28(5):779-786. PubMed ID: 33600068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients.
    Shrivastava S; Kottilil S; Sherman KE; Masur H; Tang L
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection.
    Márquez M; Romero-Cores P; Montes-Oca M; Martín-Aspas A; Soto-Cárdenas MJ; Guerrero F; Fernández-Gutiérrez C; Girón-González JA
    PLoS One; 2015; 10(3):e0119568. PubMed ID: 25775475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
    Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
    J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR.
    Saracino A; Bruno G; Scudeller L; Ladisa N; de Gennaro N; Allegrini M; Monno L; Angarano G
    J Clin Virol; 2016 Aug; 81():94-9. PubMed ID: 27371888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
    Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.